About RedShift BioAnalytics
RedShift BioAnalytics is a private company based in Boxborough, Massachusetts. It has reported $60,501,858 raised in nine offerings on Form D since January 2013. Its chief executive is Thomas O'Lenic.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 12, 2025 | Jun 26, 2025 | $5,914,304of $7.0M target | 8 | $739K | EquityRule 506(b) | Form D ↗ |
| Mar 21, 2024 | Apr 3, 2024 | $5,000,000of $7.0M target | 6 | $833K | EquityRule 506(b) | Form D ↗ |
| Oct 15, 2021 | Oct 29, 2021 | $9,999,998of $19.9M target | 12 | $833K | EquityRule 506(b) | Form D ↗ |
| Dec 17, 2020 | Dec 23, 2020 | $6,400,511of $6.4M target | 6 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Sep 21, 2018 | Oct 22, 2018amended Dec 11, 2019 | $18,250,000of $18.3M target | 11 | $1.6M | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 22, 2017 | Mar 8, 2017 | $10,783,718fully sold | 10 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Sep 21, 2015 | Oct 2, 2015 | $998,139of $2.0M target | 4 | $249K | EquityRule 506(b) | Form D ↗ |
| Mar 31, 2014 | Apr 3, 2014 | $751,549of $1.7M target | 4 | $187K | EquityRule 506(b) | Form D ↗ |
| Dec 18, 2012 | Jan 11, 2013 | $2,403,639of $2.8M target | 11 | $218K | Equity06 | Form D ↗ |
| Total, nine offerings | $60,501,858 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RedShift BioAnalytics's Form D filed Jun 26, 2025.
Earlier filings also listed Mark Cafazzo (director, last listed Apr 2024), Amol Chaubal (director, last listed Apr 2024), Julien Bradley (chief executive officer and director, last listed Oct 2021), Charles Purtell (director, last listed Oct 2021), Rob Carson (director, last listed Dec 2020), Eugene Ma (executive officer, last listed Dec 2019), Charles Marshall (president and director, last listed Dec 2019) and Bryson Holliman (director, last listed Dec 2019).